Drug Discovery 2021 Event
LaboratoryThe ELRIG (European Laboratory Research & Innovation Group) UK has publicised the details for the Drug Discovery 2021 Event at the Exhibition Centre ACC in Liverpool.
ELRIG UK’s Drug Discovery is coming back with an objective to inspire valuable conversations regarding crucial topics and future changes in preclinical drug discovery.
“The companies selected for our Innovation AveNEW are given the opportunity to raise awareness of their new company, product or service to a global audience“
The event comprises of conferences discussing new methods in infection biology diseases and advances in biomarkers and diagnostics, among many other insightful topics.
The SLAS (Society for Laboratory Automation and Screening) will use its Innovation AveNEW to highlight up and coming innovations and corporations. Nominated businesses will have the chance to feature in an episode of the SLAS New Matter podcast and obtain admission to an entrepreneurial workshop. The best candidate will have a supplementary opportunity to partake in the SLAS Conference & Exhibition in Boston or Dublin

The general manager of ELRIG UK, Sanj Kumar, said “This last year has seen unprecedented scientific progress, and ELRIG UK is committed to ensuring that our events provide highly relevant networking opportunities and content to support this continued success. ELRIG Drug Discovery is widely recognised as Europe’s largest meeting place on the application of drug discovery, and we are proud to partner with SLAS, an organisation at the industry forefront, to promote the most exciting emerging products, services and companies in Europe.”
CEO of SLAS, Vicki Loise, said “The companies selected for our Innovation AveNEW are given the opportunity to raise awareness of their new company, product or service to a global audience. At SLAS, we are very pleased to partner with ELRIG UK, and we are confident that the inclusion of our Innovation AveNEW in this year’s Drug Discovery programme will complement its mission to provide freely accessibly scientific content, promotion and networking opportunities.”